MDVL · Medavail Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405.0K | $620.0K | - | $11.46M | $11.18M | $9.11M | - | $5.79M | $5.03M | $4.03M |
| Cost of Revenue | $227.0K | $363.0K | - | $10.17M | $10.27M | $8.61M | - | $5.61M | $4.86M | $3.71M |
| Gross Profit | $178.0K | $257.0K | - | $1.29M | $918.0K | $501.0K | - | $186.0K | $173.0K | $320.0K |
| R&D | $145.0K | $176.0K | - | $178.0K | $281.0K | $493.0K | - | $232.0K | $201.0K | $168.0K |
| SG&A | $4.37M | $4.96M | - | $6.09M | $6.10M | $6.54M | - | $6.80M | $6.65M | $6.51M |
| Total Operating Expenses | $4.63M | $5.27M | - | $11.21M | $12.34M | $9.97M | - | - | - | - |
| D&A | - | $671.0K | - | $300.0K | $300.0K | $286.0K | - | $300.0K | $300.0K | $295.0K |
| Operating Income | ($4.45M) | ($5.01M) | - | ($11.49M) | ($11.42M) | ($12.77M) | - | ($11.03M) | ($10.46M) | ($9.65M) |
| Interest Expense | $146.0K | $169.0K | - | $315.0K | $276.0K | $254.0K | - | $260.0K | $277.0K | $179.0K |
| Income Tax | $0 | - | - | $0 | $24.0K | $0 | - | $0 | $0 | $0 |
| Net Income | ($5.79M) | ($17.33M) | - | ($11.81M) | ($11.72M) | ($13.02M) | - | ($11.27M) | ($10.46M) | ($9.45M) |
| EPS - Basic | - | - | - | ($0.15) | ($0.17) | ($0.40) | - | ($0.34) | ($3.35) | ($3.15) |
| EPS - Diluted | - | - | - | ($0.15) | ($0.17) | ($0.40) | - | ($1.22) | ($3.35) | ($3.15) |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.36M | $18.80M | $11.44M | $27.20M | $29.20M | $5.27M | $19.69M | $35.88M | $48.73M | $47.58M |
| Accounts Receivable | $292.0K | $207.0K | $2.21M | $2.26M | $2.08M | $1.75M | $1.19M | $1.07M | $1.06M | $1.40M |
| Inventory | $10.06M | $8.70M | $6.94M | $6.40M | $5.62M | $5.09M | $3.92M | $4.25M | $3.17M | $3.12M |
| Accounts Payable | $796.0K | $898.0K | $1.68M | $2.01M | $2.48M | - | $4.01M | - | - | - |
| Current Assets | $27.05M | $32.53M | $23.93M | $39.40M | $40.95M | $15.89M | $27.39M | $42.37M | $54.06M | $53.62M |
| Total Assets | $29.91M | $35.71M | $33.13M | $49.85M | $52.83M | $27.69M | $38.14M | $52.10M | $61.25M | $59.54M |
| Current Liabilities | $4.16M | $5.13M | $5.94M | $7.06M | $8.45M | $9.37M | $7.50M | $9.13M | $8.92M | $6.67M |
| Long-term Debt | $1.51M | $1.43M | $4.80M | $9.75M | $9.68M | $9.61M | $9.54M | $9.47M | $9.41M | $0 |
| Total Liabilities | $6.86M | $31.55M | $12.31M | $18.55M | $20.05M | $21.08M | $19.07M | $20.88M | $19.15M | $7.46M |
| Stockholders' Equity | $23.05M | $4.17M | $20.82M | $31.31M | $32.79M | $6.62M | $19.07M | $31.22M | $42.10M | $52.08M |
| Retained Earnings | ($262.83M) | ($257.04M) | ($239.71M) | ($228.64M) | ($216.83M) | ($205.11M) | ($192.09M) | ($179.46M) | ($168.19M) | ($157.73M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($5.21M) | - | - | - | ($13.26M) | - | - | - | ($9.83M) |
| Investing Cash Flow | - | ($17.0K) | - | - | - | ($852.0K) | - | - | - | ($203.0K) |
| Financing Cash Flow | - | $12.58M | - | - | - | ($23.0K) | - | - | - | $189.0K |
| CapEx | - | $17.0K | - | - | - | $343.0K | - | - | - | $154.0K |
| Free Cash Flow | - | ($5.23M) | - | - | - | ($13.61M) | - | - | - | ($9.98M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 44.0% | 41.5% | - | 11.3% | 8.2% | 5.5% | - | 3.2% | 3.4% | 7.9% |
| Operating margin | -1099.8% | -808.2% | - | -100.3% | -102.1% | -140.1% | - | -190.3% | -208.0% | -239.7% |
| EBITDA margin | - | -700.0% | - | -97.6% | -99.4% | -137.0% | - | -185.2% | -202.0% | -232.3% |
| Net margin | -1429.9% | -2795.2% | - | -103.0% | -104.8% | -142.9% | - | -194.6% | -208.0% | -234.7% |
| Free cash flow margin | - | -843.1% | - | - | - | -149.3% | - | - | - | -247.9% |
| FCF / Net income | - | 0.30 | - | - | - | 1.04 | - | - | - | 1.06 |
| R&D / Revenue | 35.8% | 28.4% | - | 1.6% | 2.5% | 5.4% | - | 4.0% | 4.0% | 4.2% |
| SG&A / Revenue | 1077.8% | 800.0% | - | 53.1% | 54.5% | 71.7% | - | 117.5% | 132.1% | 161.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.4% | -48.5% | - | -23.7% | -22.2% | -47.0% | - | -21.6% | -17.1% | -15.9% |
| Return on equity | -25.1% | -415.7% | - | -37.7% | -35.7% | -196.9% | - | -36.1% | -24.9% | -18.1% |
| Return on invested capital | -14.3% | - | - | -22.1% | -21.2% | -62.2% | - | -21.4% | -16.0% | -14.6% |
| Liquidity | ||||||||||
| Current ratio | 6.51 | 6.34 | 4.03 | 5.58 | 4.85 | 1.70 | 3.65 | 4.64 | 6.06 | 8.04 |
| Quick ratio | 4.09 | 4.64 | 2.86 | 4.68 | 4.18 | 1.15 | 3.13 | 4.17 | 5.70 | 7.57 |
| Cash ratio | 3.46 | 3.66 | 1.93 | 3.85 | 3.46 | 0.56 | 2.62 | 3.93 | 5.46 | 7.13 |
| Leverage | ||||||||||
| Debt / Equity | 0.07 | 0.34 | 0.23 | 0.31 | 0.30 | 1.45 | 0.50 | 0.30 | 0.22 | 0.00 |
| Debt / Assets | 0.05 | 0.04 | 0.14 | 0.20 | 0.18 | 0.35 | 0.25 | 0.18 | 0.15 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -30.5x | -29.7x | - | -36.5x | -41.4x | -50.3x | - | -42.4x | -37.8x | -53.9x |
| Equity multiplier | 1.30 | 8.57 | 1.59 | 1.59 | 1.61 | 4.19 | 2.00 | 1.67 | 1.45 | 1.14 |
| Liabilities / Assets | 0.23 | 0.88 | 0.37 | 0.37 | 0.38 | 0.76 | 0.50 | 0.40 | 0.31 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.02 | - | 0.23 | 0.21 | 0.33 | - | 0.11 | 0.08 | 0.07 |
| Inventory turnover | 0.02 | 0.04 | - | 1.59 | 1.83 | 1.69 | - | 1.32 | 1.53 | 1.19 |
| Days sales outstanding | 263d | 122d | - | 72d | 68d | 70d | - | 68d | 77d | 127d |
| Days inventory outstanding | 16184d | 8749d | - | 230d | 200d | 216d | - | 277d | 238d | 307d |
| Days payable outstanding | 1280d | 903d | - | 72d | 88d | - | - | - | - | - |
| Cash conversion cycle | 15167d | 7968d | - | 230d | 179d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -96.4% | -93.2% | - | 97.9% | 122.3% | 126.3% | - | 1094.2% | 1428.9% | 1288.6% |
| Revenue CAGR (3y) | 7.2% | 28.8% | - | 219.9% | 317.2% | 294.0% | - | 230.8% | 285.2% | - |
| Revenue CAGR (5y) | 35.7% | - | - | 135.0% | 185.5% | 175.9% | - | 171.9% | 137.9% | 83.2% |
| Gross profit growth (YoY) | -80.6% | -48.7% | - | 594.6% | 430.6% | 56.6% | - | -21.5% | 10.2% | 142.4% |
| Operating income growth (YoY) | 61.0% | 60.8% | - | -4.2% | -9.1% | -32.3% | - | -1264.5% | -1269.5% | -1031.4% |
| Net income growth (YoY) | 50.6% | -33.1% | - | -4.7% | -12.0% | -37.8% | - | -1283.2% | -1257.2% | -991.5% |
| EPS growth (YoY) | - | - | - | 87.7% | 94.9% | 87.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 61.6% | - | - | - | -36.3% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -29.7% | -37.0% | 9.2% | 0.3% | -22.1% | -87.3% | -68.8% | 1443.9% | 1388.6% | 1892.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$22.13M totalRetail Pharmacy Services Segment$20.20M · 91.3%
Pharmacy Technology Segment$1.93M · 8.7%
Product / service
$44.21M totalPharmacy And Hardware$21.12M · 47.8%
Retail Pharmacy$20.20M · 45.7%
Service$1.01M · 2.3%
Professional Services$551.0K · 1.2%
Hardware$470.0K · 1.1%
Subscription$400.0K · 0.9%
Software$259.0K · 0.6%
Maintenance And Support$161.0K · 0.4%
Installation$39.0K · 0.1%
Peer comparison
Same SIC group: Retail-Drug Stores and Proprietary Stores
Comparing MedAvail Holdings against the 5 most active filers in the same SIC group.